Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer

BACKGROUND: Durable responses to immune-checkpoint blocking therapy (ICT) targeting programmed cell death protein-1/ligand-1 (PD-1/PD-L1) have improved outcomes for patients with triple negative breast cancer (TNBC). Unfortunately, only 19–23% of patients benefit from ICT. Hence, non-invasive strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wan-Ling, Zhang, Yong-Qu, Luo, Xiang-Jie, Zhu, Yuan-Yuan, Song, Liang, Ming, Zi-He, Zhang, Li-Xin, Li, Meng-Jun, Lv, Rui-Chan, Zhang, Guo-Jun, Chen, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497065/
https://www.ncbi.nlm.nih.gov/pubmed/37705867
http://dx.doi.org/10.2147/IJN.S417944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497065/
https://www.ncbi.nlm.nih.gov/pubmed/37705867
http://dx.doi.org/10.2147/IJN.S417944

Ejemplares similares